primary studies - published RCT

A preliminary study on the effect of anti-inflammatory treatment in cystic fibrosis patients with Pseudomonas aeruginosa lung infection.

Code: CN-00173505 **Year:** 1994 **Date:** 1994 **Author:** Sordelli DO

Study design (if review, criteria of inclusion for studies)

Randomised 4-way cross-over design

Participants

n = 12 Males = 5 Females = 7. Mean age 29.9 years, range 16 years to 46 years (SD 9.4 years)

Interventions

Mannitol 300 mg (encapsulated dry powder) Pre-treated with terbutaline 1000 mcg (turbulhaler) HS 6% 7 ml IS (0.9%)+ matched voluntary cough Empty capsules with matched voluntary coughs All given as a single dose

Outcome measures

Sputum isotope % clearance at 30 minutes Sputum isotope clearance at 90 minutes* Mucociliary clearance*

Main results

Eight patients did not complete the study for diverse reasons. Fifteen of 17 patients taking placebo had decreased respiratory function status by the end of the study while 9 of 16 patients under piroxicam treatment retained their baseline values or improved their respiratory status. Piroxicam- treated patients required less hospitalization (192 d) than those receiving placebo (301 d).

Authors' conclusions

A long-term, large scale study would now be required to confirm the results of this preliminary investigation and to establish the significance of anti-inflammatory treatment with cyclooxgenase inhibitors to prevent lung tissue damage in patients with chronic obstructive pulmonary disease and Gram-negative pulmonary infection.

http://www.mrw.interscience.wiley.com/cochrane/clcentral/articles/505/CN-00173505/frame.html

See also

INT J IMMUNOPATHOL PHARMACOL YR: 1994 VL: 7 DE: RCT NO: 2

Keywords

Adolescent; Adult; Anti-Inflammatory Agents; Bacterial Infections; Child; Infection; pharmacological_intervention; Piroxicam; Pneumonia; Pseudomonas aeruginosa; Pseudomonas; Respiratory Tract Infections; Capsules; Powders; Mannitol; Airway clearance drugs -expectorants- mucolytic- mucociliary-; Respiratory System Agents; Anti-Inflammatory Agents - excl Steroids; Respiratory Tract Diseases;